Role of Growth Hormone in Countering the Effects of Anxiety and Depression in Women Undergoing in-vitro Fertilization-Embryo Transfer [Letter]
Abdul Moiz Sahito
Dow Medical College, Karachi, Pakistan
Correspondence: Abdul Moiz Sahito
Dow Medical College, Mission Road, New Labour Colony Nanakwara, Karachi, Sindh, Pakistan
Email [email protected]
I have read the article entitled “The analysis of anxiety and depression in different stages of in-vitro fertilization-embryo transfer in couples in China” by Liu et al published in Neuropsychiatric Disease and Treatment.1 I want to acknowledge the authors for this successful research article and make some contributions.
In the article, the effect of anxiety and depression on the outcomes of IVF-ET has been studied indicating that there is high incidence of anxiety and depression in couples undergoing IVF-ET, particularly in women. Although the study concluded that there is no significant association between anxiety and depression and IVF-ET outcomes (p>0.05), there is still a need of a much more extensive investigation.
Regarding this matter, I have something to suggest. I think that this study should have included an examination of changes in hormonal index of women involved in the study. While the study conducted by An et al2 did an examination on the changes in stress influencing the outcomes of IVF via the activation of hypothalamus-pituitary-adrenal (HPA) axis, there is still a need of a thorough study which involves hormones that are part of the HPA axis. In this matter, role of Growth Hormone should be investigated in increasing the efficacy of IVF-ET in women with high level of anxiety and depression. The randomized control trial, conducted by Hart,3 conclusively showed that pretreatment with GH alleviates Oxidative Stress (OS), involved in the pathogenesis of Poor Ovarian Responders (POR), and improves oocyte quality and outcomes of PORs.
Therefore, the potential applications of GH in women with anxiety and depression related issues does warrant attention and should be thoroughly investigated. For this, I suggest that a study consisting of two groups of women diagnosed with clinical anxiety and depression undergoing IVF should be done, with one group pretreated with GH, and both examined to find any conclusive indication that GH pretreatment increases the efficacy of the IVF-ET procedures by countering the effects of severe anxiety and depression.
The author reported no conflicts of interest for this communication.
1. Liu YF, Fu Z, Chen SW, He XP, Fan LY. The analysis of anxiety and depression in different stages of in vitro fertilization-embryo transfer in couples in China. Neuropsychiatr Dis Treat. 2021;17:649. doi:10.2147/NDT.S287198
2. An Y, Wang Z, Ji H, Zhang Y, Wu K. Pituitary-adrenal and sympathetic nervous system responses to psychiatric disorders in women undergoing in vitro fertilization treatment. Fertil Steri. 2011;96(2):404–408. doi:10.1016/j.fertnstert.2011.05.092
3. Hart RJ. Use of growth hormone in the IVF treatment of women with poor ovarian reserve. Front Endocrinol (Lausanne). 2019;10:500. doi:10.3389/fendo.2019.00500
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.